Publication:
COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients

Simple item page
dc.contributor.authorÖZGEN, ZÜLEYHA
dc.contributor.authorsÖZGEN Z., Aksoy H., Cakici O. A., Aksu A. E. K., Erdem O., Polat A. K., Gürel M. S.
dc.date.accessioned2023-03-27T09:56:42Z
dc.date.available2023-03-27T09:56:42Z
dc.date.issued2022-05-01
dc.description.abstractThere are safety concerns in the treatment of pemphigus patients with immunosuppressants, particularly rituximab (RTX), in times of the COVID-19 pandemic. In the beginning, the reports were more pessimistic. However, few reports have recently pointed to manageable courses in this patient group. Therefore, we investigated the disease characteristics and demographic features of pemphigus patients in the period of the COVID-19 pandemic. We aimed to investigate the impact of immunosuppressants on the course of COVID-19 in pemphigus patients. Also, we tried to find out the rate of flares due to COVID-19 and SARS-Cov-2 vaccines. This multicenter study included 247 patients with pemphigus from three tertiary dermatology clinics with the specialized outpatient clinic for autoimmune blistering diseases. Patients were asked standardized questions in person or via telephone calls. Also, demographic data were collected from patients\" files. Two hundred forty-four of 247 patients took the survey between August and September 2021. The data of three patients were obtained from the National Health System. We collected the data of all pemphigus patients who visited the clinics at least once in the past 3 years. Among 51 patients having COVID-19, 40 had a non-serious disease, whereas 11 required hospitalization. One patient died because of COVID-19 infection. The number of patients is limited, and data depends mainly on patients\" statements. RTX treatment does not require additional safety cautions than other immunosuppressives.
dc.identifier.citationÖZGEN Z., Aksoy H., Cakici O. A., Aksu A. E. K., Erdem O., Polat A. K., Gürel M. S., "COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients", DERMATOLOGIC THERAPY, cilt.35, sa.5, 2022
dc.identifier.doi10.1111/dth.15417
dc.identifier.issn1396-0296
dc.identifier.issue5
dc.identifier.urihttps://www.scopus.com/record/display.uri?eid=2-s2.0-85126047653&origin=resultslist&sort=plf-f&src=s&st1=COVID-19+severity+and+SARS-Cov-2+vaccine+safety+in+pemphigus+patients&sid=f617de590c24b582d72d966df3152d4a&sot=b&sdt=b&sl=84&s=TITLE-ABS-KEY%28COVID-19+severity+and+SARS-Cov-2+vaccine+safety+in+pemphigus+patients%29&relpos=2&citeCnt=5&searchTerm=
dc.identifier.urihttps://hdl.handle.net/11424/287853
dc.identifier.volume35
dc.language.isoeng
dc.relation.ispartofDERMATOLOGIC THERAPY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectDermatoloji
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectInternal Medicine Sciences
dc.subjectDermatology
dc.subjectDERMATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectDERMATOLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectCOVID-19
dc.subjectpemphigus
dc.subjectrituximab
dc.subjectSARS-CoV-2
dc.subjectvaccine
dc.subjectDISEASES
dc.subjectCOVID-19
dc.subjectpemphigus
dc.subjectrituximab
dc.subjectSARS-CoV-2
dc.subjectvaccine
dc.titleCOVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients
dc.typearticle
dspace.entity.typePublication
local.avesis.id994952bd-5bca-4ccf-981e-6ea573d03861
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication296d22ba-c452-4791-b225-11f2e7241464
relation.isAuthorOfPublication.latestForDiscovery296d22ba-c452-4791-b225-11f2e7241464

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
8.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs